Fleury S.A. (FLRY3) Earnings Call Transcripts
Fleury S.A.'s Latest Earnings Call - Q1 FY2026
In the first quarter of 2026, Fleury S.A. (FLRY3:BR) reported a gross revenue of BRL 2.4 billion, reflecting a 10.1% year-over-year growth, driven primarily by the B2C segment which grew 15.1%. Net income increased by 12.2% to BRL 201.2 million, with a net margin of 9.1%. Management maintained a positive outlook, emphasizing sustainable growth and expansion, particularly with the launch of their new Fleury Lifecare service. No changes to guidance were noted, but the company expressed confidence in its growth trajectory and capital allocation discipline.
Reported metrics
| Metric | Value |
|---|---|
| Gross Revenue | BRL 2.4 billion (beat) |
| Net Income | BRL 201.2 million (beat) |
| EBITDA | BRL 606 million (beat) |
| EBITDA Margin | 27.3% (beat) |
| Net Margin | 9.1% (beat) |
| Operational Cash Flow | BRL 264.6 million (miss) |
Guidance from management
Management maintained a positive outlook for 2026, emphasizing sustainable growth and the potential for market share gains, particularly in the premium segment. No specific numerical guidance was provided, but they expressed confidence in their strategic direction.
What analysts pressed on
Analysts raised concerns about the decrease in operational cash flow and the potential impact of seasonal factors on future cash generation. There were also questions regarding the competitive landscape in diagnostic medicine and the company's ability to maintain market share amidst aggressive competition.
Main topics on the call
- Strong Revenue Growth — Fleury's gross revenue reached BRL 2.4 billion, marking a 10.1% increase year-over-year. The B2C segment was particularly strong, with a 15.1% growth, indicating robust demand for their services. Management stated, "Our ...
- Launch of Fleury Lifecare — The company is launching Fleury Lifecare, a new service aimed at individuals over 35, focusing on preventive and customized care. This initiative is part of their 100-year anniversary celebrations and represents a strate...
- Improved EBITDA and Net Income — EBITDA for the quarter was reported at BRL 606 million, with a margin of 27.3%, slightly up from the previous year. Net income rose to BRL 201.2 million, reflecting a 12.2% increase. Management highlighted, "Net margin i...
- Operational Efficiency — Fleury demonstrated operational discipline with a decrease in operational expenses relative to revenue, amounting to BRL 260 million. This reflects their focus on cost management and efficiency. Management stated, "Opera...
Read the full Fleury S.A. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Fleury S.A.
Fleury S.A. (FLRY3) is a publicly listed company in the Health Care Providers and Services industry, within the Health Care sector. It trades on BOVESPA and is based in BR. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 28 calls on record spanning February 20, 2020 to May 8, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 Fleury S.A. earnings call transcripts on record, spanning February 20, 2020 to May 8, 2026. Based on this history, Fleury S.A. reports quarterly. The most recent call on file is dated May 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- FLRY3
- Exchange
- BOVESPA
- Country
- BR
- Sector
- Health Care
- Calls on record
- 28
- First call
- February 20, 2020
- Most recent
- May 8, 2026
- Reporting cadence
- quarterly